Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-HER-2 in Advanced HER-2 Positive Solid Tumors
NCT01935843Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CART-HER-2 in HER2-positive solid tumor, breast cancer, gastric cancer (GC), non-small cell lung cancer (NSCLC), ovarian cancer, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
CART-HER-2
03
Conditions
HER2-positive solid tumorbreast cancergastric cancer (GC)non-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT01935843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935843.